Feature | Ventricular Assist Devices (VAD) | June 04, 2018

Medtronic HeartWare HVAD System Recalled Due to Unintended Disconnection of Power Source

FDA Class I recall includes all 204,017 HVADs made since 2006

The Medtronic HeartWare Ventricular Assist Devices (HVAD) has a Class I FDA recall.
Image of the device showing the internal HVAD pump, which is connected to the external controller by a driveline cable through the skin. The controller is connected externally to the monitor, the AC adapter, and the battery.

Image of the device showing the internal HVAD pump, which is connected to the external controller by a driveline cable through the skin. The controller is connected externally to the monitor, the AC adapter, and the battery.

June 4, 2018 — The U.S. Food and Drug Administration said Medtronic initiated a Class 1 recall all 204,017 of its HeartWare Ventricular Assist Devices (HVAD) produced between March 2006 to May 2018. 

Medtronic said there is a possibility for an interruption to occur in the electrical connection between the system’s power source (battery, AC adapter, or DC adapter) and the HVAD controller. This interruption to the electrical connection, which occurs when the power source is still physically connected, is caused by oxidation on the connecting surfaces between the power source connector and the controller’s power source socket. The interruptions to the electrical connection could cause unintended intermittent electrical disconnection, which could result in a pump stop. A pump stop could cause patient harm such as exacerbation of heart failure symptoms, or symptoms such as mild weakness, dizziness, anxiety, nausea, loss of consciousness, or death.

The HeartWare HVAD is indicated for use as a bridge to cardiac transplantation in patients who are at risk of death from end-stage left ventricular heart failure. It functions as a pump that helps the heart deliver blood to the rest of the body. The HeartWare system is designed for in-hospital and out-of-hospital settings, including transportation via fixed wing aircraft or helicopter. These indications have been expanded to include HVAD use for myocardial recovery, or as destination therapy in patients for whom subsequent transplantation is not planned.

Medtronic said the recall encompasses all HVAD systems manufacturing and distribution between March 2006 to May 2018, which includes 204,017 devices in the United States. 

Medtronic sent a letter on May 2, 2018 advising hospitals and physicians to:
   • Reinforce the importance of always ensuring two power sources are connected at all times
   • Reinforce best practice guidance for managing power sources when going to sleep and awakening
   • Instruct patients to report any persistent, unexpected audible tones to the VAD team for additional instructions

The FDA released a public statement about the HVAD recall June 4. 

Customers who need additional information about this recall can contact Medtronic Customer Service at (877) 367-4823

This is the second major LVAD recall in the past month. In May, Abbott has initiated a Class I recall of more than 4,000 HeartMate 3 Left Ventricular Assist systems due to a malfunction in the device’s outflow graft assembly. The company said the malfunction may cause the outflow graft to twist and close up (occlusion) over time. Occlusion of the outflow graft can reduce or stop pump flow and set off a persistent low flow alarm in the system. A reduction in pump can lead to serious adverse events such as blood clots and death. 

Related Content:

FDA Recall Database Document for HVAD Recall

Medtronic HeartWare HVAD System Approved for Destination Therapy

Abbott Recalls the HeartMate 3 Left Ventricular Assist System

 

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Antithrombin Drug Ineffective in Heart Failure With Sinus Rhythm and Coronary Disease
News | Heart Failure | September 07, 2018
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction...
Overlay Init